作者: Rüdiger Pipkorn , Waldemar Waldeck , Bernd Didinger , Mario Koch , Gabriele Mueller
DOI: 10.1002/PSC.1108
关键词:
摘要: Hormone-refractory prostate cancer (HRPC), insensitive to most cytostatic interventions, features low response rates and bad prognosis. Studies with HRPC treated temozolomide (TMZ) showed a poor the results were discouraging. Therefore, TMZ has been considered be ineffective for treatment of patients symptomatic progressive HRPC. A solution this problem is demonstrated in study by combining proper solid-phase peptide synthesis chemoselective new 'click' chemistry based on Diels-Alder reaction 'inverse-electron-demand' (DAR(inv)) construction highly efficient TMZ-BioShuttle which ligated transporter subcellular address molecules. The transport targeted nuclei resulted much higher efficiency better pharmacological effects. reformulation achieved vitro killing cells. Accordingly, potential tumors was dramatically enhanced even tenfold lower concentration than applied normally. This may well suited chemotherapy other agents or radiation therapy.